Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Longest Review: Inside Ovation’s Wait For Sabril

This article was originally published in The Pink Sheet Daily

Executive Summary

The anticonvulsant vigabatrin is one of a dozen products for which FDA has missed user fee deadlines so far this year. Fifteen years after the NDA first was submitted, maybe that shouldn’t be a surprise.

You may also be interested in...



Ovation’s Sabril Visual Defect Is Topic Of FDA Meeting; Is End To Longest Review In Sight?

FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will evaluate vigabatrin for two epilepsy indications at a meeting rescheduled for Jan. 7-8.

Ovation’s Sabril Visual Defect Is Topic Of FDA Meeting; Is End To Longest Review In Sight?

FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will evaluate vigabatrin for two epilepsy indications at a meeting rescheduled for Jan. 7-8.

Takeda’s Alogliptin Falls Prey To FDA Slowdown

Delay is no bellwether for oral anti-diabetic drugs, the firm says.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel